Effect of pre-existing immunity to flaviviruses on balanced induction of neutralizing antibodies by a dengue tetravalent DNA vaccine in mice

Journal of Vaccines and Vaccination

Volumn 1, Issue 1, 2010, Pages

  Konishi, Eiji ^a,b   Takizawa, Yamato ^a  

^a KOBE UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dengue; DNA vaccine; Japanese encephalitis; Neutralizing antibody; Preimmunity

Indexed keywords

EID: 82855175704     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000102     Document Type: Article

References (35)

1. Bancroft WH, Scott RM, Eckels KH, Hoke CH Jr, Simms TE et al. (1984) Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. J Infect Dis 149: 1005-1010.
2. Barnett ED, Kozarsky PE, Steffen R (2008) Vaccines for International travel. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines 5th edition, Saunders Elsevier, Maryland Heights, pp 1431-52.
3. Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS (2006) Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol 19: 10-32.
4. Burke DS, Nisalak A, Johnson DE, Scott RM (1988) A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 38: 172-180
5. Feltquate DM, Heaney S, Webster RG, Robinson HL (1997) Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 158: 2278-2284
6. Green S, Rothman A (2006) Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 19: 429-436.
7. Gubler DJ, Kuno G, Markoff L (2007) Flaviviruses. In: Knipe DM, Howley PM (eds) Fields virology 5th edition, Lippincott Williams & Willkins, Philadelphia, pp 1153-252.
8. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K et al. (2006) Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever preimmunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2: 60-67.
9. Guy B, Barban V, Mantel N, Aguirre M, Gulia S et al (2009) Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 80: 302-311.
10. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, et al. (2010) Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28: 632-649.
11. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, et al. (1990) Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 42: 179-184.
12. Halstead SB (2007) Dengue. Lancet 370(9599): 1644-1652.
13. Halstead SB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60:421-467.
14. Halstead SB, Vaughn DW (2008) Dengue vaccines. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines 5th edition, Saunders Elsevier, Maryland Heights, pp 1155-61.
15. Hombach J, Cardosa ML, Sabchareon A, Vaughn DW, Barrett AD (2007) Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine 25: 4130-4139.
16. Imoto J, Konishi E (2007) Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine. Vaccine 25: 1076-1084.
17. Kanesa-Thasan N, Sun W, Ludwig GV, Rossi C, Putnak JR et al. (2003) Atypical antibody responses in dengue vaccine recipients. Am J Trop Med Hyg 69: 32-38.
18. Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S et al. (2006) Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24:1238-1241.
19. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS (1989) Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg. 40: 444-451.
20. Konishi E, Kosugi S, Imoto J (2006) Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24: 2200-2207.
21. Konishi E, Terazawa A, Imoto J (2003) Simultaneous immunization with DNA and protein vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to induce neutralizing antibody in mice. Vaccine 21: 1826-32.
22. Konishi E, Yagawa K, Yamanaka A (2008) Vero cells infected with vaccinia viruses expressing Japanese encephalitis virus envelope protein induce polykaryocyte formation under neutral conditions. Jpn J Infect Dis 61: 410-411.
23. Kuno G (2003) Serodiagnosis of flaviviral infections and vaccinations in humans. Adv Virus Res. 61: 3-65.
24. Kurane I, Mady BJ, Ennis FA (1991) Antibody-dependent enhancement of dengue virus infection. Rev Med Virol 1: 211-221.
25. Lindenbach BD, Thiel HJ, Rice CM (2007) Flaviviridae: the viruses and their replication. In: Knipe DM, and Howley PM (eds) Fields virology 5th edition, Lippincott Williams & Willkins, Philadelphia, pp 1101-52.
26. Lu S, Wang S, Grimes-Serrano JM (2008) Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 7: 175-191.
27. Monath TP, Cetron MS, Teuwen DE (2008) Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines 5th edition, Saunders Elsevier, Maryland Heights, pp 959-1055.
28. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, et al. (2010) A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 201: 370-307.
29. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat P, Attanath P et al. (2002) Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66: 264-272.
30. Sabin AB (1952) Research on Dengue during World War II. Am J Trop Med Hyg 1: 30-50.
31. Stephenson JR (2005) Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ 83: 308-314.
32. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, et al. (2009) Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. Hum Vaccin 5: 33-40.
33. Whitehead SS, Durbin AP (2010) Prospects and challenges for dengue virus vaccine development. In: Hanley KA, Weaver SC (eds) Frontiers in Dengue Virus Research. Caister Academic Press, Norfolk UK, pp 221-237.
34. Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, Thumar B, Ankrah S, Rock MT, McKinney BA, MurphyBR, Schmidt AC (2009) Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am J Trop Med Hyg 81: 834-841.
35. Yamanaka A, Kosugi S, Konishi E (2008) Infection-enhancing and-neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J Virol 82: 927-37.